

Extracellular vesicle fusion visualized by cryo-electron microscopy

Mattia I. Morandi¹, Petro Busko¹, Efrat Ozer-Partuk¹, Suman Khan¹, Giulia Zarfati¹, Yael Elbaz-Alon¹, Paula Abou Karam¹, Tina Napso Shogan², Lana Ginini², Ziv Gil^{2,3}, Neta Regev-Rudzki^{1,*} and Ori Avinoam¹

¹Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel

²Faculty of Health, Bar Ilan University, Ramat-Gan 5290002, Israel

³Head and Neck Center, Holy Family Hospital, Nazareth 1641100, Israel

*To whom correspondence should be addressed: Email: neta.regev-rudzki@weizmann.ac.il; ori.avinoam@weizmann.ac.il

Edited By: Ian Wilson.

Abstract

Extracellular vesicles (EVs) transfer bioactive molecules between cells in a process reminiscent of enveloped viruses. EV cargo delivery is thought to occur by protein-mediated and pH-dependent membrane fusion of the EV and the cellular membrane. However, there is a lack of methods to identify the fusion proteins and resolve their mechanism. We developed and benchmarked an *in vitro* biophysical assay to investigate EV membrane fusion. The assay was standardized by directly comparing EV and viral fusion with liposomes. We show that EVs and retroviruses fuse with liposomes mimicking the membrane composition of the late endosome in a pH- and protein-dependent manner. Moreover, we directly visualize the stages of membrane fusion using cryo-electron tomography. We find that, unlike most retroviruses, EVs remain fusogenic after acidification and reneutralization. These results provide novel insights into the EV cargo delivery mechanism and an experimental approach to identify the EV fusion machinery.

Significance Statement:

Extracellular vesicles (EVs) are membrane-bound compartments containing bioactive cargos, released from cells to mediate intercellular communication. EV cargo delivery is thought to occur via EV-to-cell membrane fusion. However, EV fusion has not been directly visualized and the fusion mechanism remains uncharacterized. We benchmark an *in vitro* assay that recapitulates EVs fusion with liposomes using enveloped viruses as control. We show that EV-liposome fusion recapitulates features previously reported for EV cargo delivery, and that the fusion process can be visualized at a nanometric resolution using cryo-electron microscopy. Moreover, our data suggest that unlike most enveloped viruses, EV fusion is not inactivated upon exposure to acidic pH in the absence of target membranes, which is consistent with biogenesis in multivesicular bodies.

Introduction

Extracellular vesicles (EVs) are membrane-enclosed compartments ranging from 50 to 500 nm in diameter loaded with proteins, lipids, RNA, and DNA. They are secreted from several cell types and generally promote physiological and pathological processes, including the immune response, cancer development, and metastasis (1–6). They are also extensively studied for their potential clinical application as diagnostic biomarkers and drug delivery systems (3, 7, 8).

EVs have been classified into three major subpopulations (i.e. microvesicles, apoptotic bodies, and exosomes), each composed of a heterogeneous pool of vesicles (9). While microvesicles and apoptotic bodies bud from the plasma membrane, exosomes bud into the lumen of multivesicular bodies (MVBs) and exit cells after MVB fusion with the cell membrane (i.e. MVB exocytosis) (10, 11). Regardless of their classification, EVs enter recipient cells from the extracellular environment primarily through vesicular uptake and must release their cargo into the cytoplasm to modulate cell physiology (12).

The biogenesis, size, and composition of EVs are remarkably similar to many enveloped single-stranded RNA viruses such as rhabdoviruses (e.g. vesicular stomatitis virus), orthomyxoviruses (e.g. influenza), and retroviruses (e.g. HIV) (13, 14). The envelopes of such viruses contain glycoproteins that function as ligands to attach the virus to specific cellular receptors and then mediate fusion between the cell membrane and the viral envelope (15). These glycoproteins are also frequently essential for virion assembly and budding (16). As such, membrane fusion has been suggested as the primary mechanism of EV cargo delivery (17–20).

EV cargo delivery has been shown to depend on proteins (19, 20) and to be triggered by low pH (17, 19, 20). Moreover, the efficiency of cargo delivery can be modulated by changing the lipid composition in the endosome (17, 18). These findings reinforce the hypothesis that most EV cargo delivery occurs by EV membrane fusion, triggered by the late endosomal milieu. Nevertheless, the fusion mechanism remains incompletely understood and it is unclear how triggering fusion by low pH is compatible with exosome biogenesis in the acidic MVBs (21).

Competing Interests: All authors declare no competing interests.

Received: April 1, 2022. Accepted: August 9, 2022

© The Author(s) 2022. Published by Oxford University Press on behalf of the National Academy of Sciences. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.




Fig. 1. EV-LUV *in vitro* system to investigate membrane fusion. (A) Graphical illustration of the EV uptake/cargo delivery pathway. (B) Comparison of the size distribution of EVs (red) and LUVs (black) measured via nanoparticle tracking analysis (NTA). (C) Representative cryo-TEM image of EVs isolated from OVCAR-3 cell supernatants and LUVs. Scale bar 100 nm. (D) Results of Fourier analysis performed on luminal region cryo-EM images, showing luminal region image and the average fast Fourier transform (FFT) obtained, alongside the FFT profile obtained for EVs (red) and LUVs (gray). Data are presented as average (open symbol) and SD (whiskers) obtained from $n = 50$ EVs and $n = 50$ LUVs from three separate imaging sessions. (E) Western blot analysis of density gradient fractions (pooled by density) and OVCAR-3 cell lysate (as a control) using antibodies against EV (Alix, CD9, and CD63) and control protein determinants (TOM20). Illustration created with BioRender.com.

Based on the biophysical assays developed to study viral fusion, we developed an *in vitro* assay to investigate EV membrane fusion by probing the interaction of EVs with artificial liposomes. Using a Förster resonance energy transfer (FRET)-based assay to directly compare EV and viral fusion at the level of membrane mixing *in vitro*, we demonstrate that EVs can fuse unilaterally to lipid membranes in a pH-dependent manner, consistent with previous studies (19, 20). Moreover, we benchmark the assay by directly comparing EVs and viruses and by resolving the fusion intermediates using cryogenic transmission electron microscopy (cryo-TEM) and electron tomography (cryo-ET). We find that in EVs, contrary to most viruses, the low-pH-trigger is reversible, as previously shown for vesicular stomatitis virus (VSV) (22, 23).

These results provide a novel insight into the mechanism of EV fusion, suggesting that viral and EV fusogens likely share structural and functional similarities and may even share common ancestors. Moreover, they establish a standard method for further functional and structural studies of the fusion process that could lead to the identification of the EV fusion machinery and become a gold standard approach in the EV fusion field.

Results

EV and large unilamellar vesicle (LUV) characterization

The delivery of the EV cargo into the host-cell cytoplasm initiates with binding to the recipient cell membrane, followed by either fusion with the plasma membrane or vesicular uptake (i.e. endocytosis) of the EV, then by fusion with the endosomal membrane (Fig. 1A) (12). To bypass this complexity and focus on the fusion process, we probed the interaction of EVs with liposomes *in-vitro*.

We purified extracellular vesicles from OVCAR-3 cell culture supernatant using OptiPrep density gradient ultracentrifugation (24) following the Minimal information for studies of extracellular vesicles (MISEV) 2018 guidelines (25). We subsequently pooled the EV fractions and pelleted them through a sucrose cushion (26). We examined EV and LUV sample size and morphology using an NTA (Figs. 1B, and S1A and B) and cryo-TEM (Fig. 1C), showing that the isolated EVs display the typical morphology and size distribution of EVs with an average diameter of 132.5 ± 2.1 nm. We also detected the known EV markers CD63, Alix, and CD9 (25), but not




Fig. 2. EV fuse in a protein- and pH-dependent manner reminiscent of viruses. (A) Illustration of the FRET-based membrane mixing assay employed to quantify fusion between EVs and liposomes. Highly FRET-efficiency labeled EVs are incubated with nonlabeled liposomes and their ability to fuse is probed by monitoring the donor fluorescent intensity after triggering. (B) Representative curves of membrane mixing assay for either retrovirus (green) or EV (orange) incubated with unlabeled LUVs at pH 7.4 (dotted line) or pH 5.0 (solid line). (C) FRET fusion assay for labeled retroviruses, EVs and LUVs, incubated with LUVs at either pH 7.4 (green) or pH 5.0 (orange), showing that retroviruses and EVs fuse with similar efficiencies. LUVs mimicked the late endosome lipid composition. (D) Representative NTA size distribution curves of EV–LUV mixtures upon incubation at pH 7.4 (green) or pH 5.0 (orange) showing an increase in vesicle size after mixing and triggering with pH 5.0. (E) FRET membrane mixing assay comparing EVs treated with proteinase K (PK, orange) or nontreated (green), incubated with late endosomal-mimicking LUVs at pH 5.0. (F) Western blot for membrane protein EV marker, PTGFRN, and intraluminal protein Alix for nontreated and PK-treated EVs, showing that proteinase only digests proteins on the surface of the EVs.

the mitochondria-specific protein TOM20, as expected with purified EVs (25) (Fig. 1E). Isolation from naïve growth medium was used as a control to verify that EVs originate from the cultured cells and not from the bovine serum (Fig. S1B).

LUVs extruded at 100 nm showed a narrow diameter distribution at 109.9 ± 2.6 nm and appeared to have lower luminal contrast than EVs (Fig. 1C). However, further analysis of the luminal regions showed that while there are statistically significant differences between the EVs and LUVs, they are not sufficiently different to unambiguously distinguish between them by cryo-EM (Figs. 1C and D, and S2).

Membrane mixing between EVs and LUVs is triggered by low pH

We then turned to methods extensively utilized in virology to study viral membrane fusion and established an *in vitro* membrane mixing assay based on FRET (Fig. 2A) to probe EV membrane fusion with lipid membranes (27–32). To benchmark the assay, we conducted the experiments with EVs and nonreplicating retroviruses, stained with the lipid dyes DiI and DiD as a FRET pair. At a steady state, DiI fluorescence emission is transferred to and absorbed by DiD. The FRET-labeled vesicles or viruses

were incubated with unlabeled LUVs. If fusion occurs, donor intensity increases due to the dilution of the vesicles or viruses by the unlabeled LUV membranes, which increases the distance between the FRET pair. The donor's fluorescence (DiI) is monitored, and its intensity is normalized to the maximum donor intensity, which is obtained by fully solubilizing the membranes using a detergent (Fig. 2A). To mimic the lipid composition of the late endosome membrane, we conducted this analysis using LUVs enriched in bisoleoyl-lysobisphosphatidic acid (LBPA) and without cholesterol (33); phosphatidylcholine (PC) and phosphatidylethanolamine (PE) lipids were also utilized, for a final molar composition of LBPA:PC:PE 70:25:5. For controls, we used labeled retroviruses (positive control for fusion) or LUVs mixed with unlabeled LUVs (negative control).

As pH acidification was shown to trigger viral (23, 34) and EV fusion (19, 20), we validated the assay by testing whether membrane mixing is pH-dependent. Incubation of the labeled EVs with unlabeled LUVs at pH 7.4 shows negligible membrane mixing, indicating nonoccurrence of fusion (Fig. 2B). Upon acidification (ranging from pH 7.4 to 5.0), we observed significant membrane mixing for EVs and viruses at comparable efficiencies ($P = 0.699$; $24.4\% \pm 10.0\%$ and $22.7\% \pm 8.7\%$, respectively; Figs. 2C and S3A). LUV control showed no significant variation in membrane mixing across the range of acidic pH values, indicating that pH alone is not sufficient to induce fusion and lipid mixing (Fig. S3A). Additionally, no membrane mixing is measured in fractions and naïve growth medium absent of EVs (Fig. S3B and C). It should be noted that the recorded fusion values between EVs and LUVs are an underestimation of the overall EV fusion capability, as we cannot account for EV-to-EV fusion, which would require mixing labeled and unlabeled EVs; they allow, however, to compare between different conditions as such underestimation is shared across samples.

If fusion occurs between EVs and LUVs, then the size distribution of the population is expected to skew towards larger vesicles upon acidification. To test size distributions under different pH conditions directly, we performed NTA analysis on the mixed EVs and LUVs at pH 7.4 compared to pH 5.0. We observed that at pH 7.4, the diameters are consistent with a mixed population of EVs and LUVs. However, the diameters shift towards larger sizes after acidification, consistent with vesicle fusion (219 ± 20 nm at pH 7.4, 300 ± 30 nm at pH 5.0, $P = 2.36E-9$; Figs. 2D and S3D). Together, these results demonstrate that EVs fuse in a process triggered by low pH, similar to viruses.

EV proteins and target membrane lipid composition are essential for fusion

Next, we examined if EV fusion is protein mediated by proteolytically "shaving" the proteins from the EV membrane using Proteinase K (PK), a broad-spectrum serine protease (35, 36). We observed a significant reduction in membrane mixing of EVs shaved with PK ($46\% \pm 18\%$ compared to NT EVs; $P = 0.00104$; Fig. 2E). PK treatment showed no significant vesicle size distribution or concentration alteration as measured by NTA (Fig. S4A). Fusion efficiency was also not affected by treatment with the protease inhibitor phenylmethylsulfonyl fluoride (PMSF), which was used to quench PK digestion (Fig. S4B). These results suggest that EV membrane proteins are critical for the fusion mechanism, consistent with a previous report showing that EV content release is protein-dependent (19). We next verified by Western blot that PK digestion removed the EV membrane protein PTGFRN (37) but

retained the luminal protein Alix, showing that EV integrity was maintained and only surface proteins were digested (Fig. 2F). We moreover confirmed via cryo-EM imaging that the EV morphology was not significantly altered upon PK treatment (Fig. S4C).

EVs fuse to late endosomal-mimicking membranes at pH 5.0 (Fig. 2C) with an efficiency comparable to viruses. To investigate whether the late-endosomal lipid composition (mainly composed of LBPA) is essential for efficient fusion, we compared EV fusion probability with late-endosome-mimicking membranes to either single-component lipid bilayer (DOPC) or early endosomal-mimicking membranes. We found that fusion does not occur when EVs interact with nonphysiological DOPC LUVs (Fig. 3A, $1.0\% \pm 1.1\%$), reinforcing the concept that lipid composition is crucial for membrane fusion (38). Moreover, we observed significantly lower fusion efficiency with early endosomal-mimicking LUVs, which are enriched in sphingomyelin (SM) and cholesterol (chol) (for a total composition of PC:PE:SM:chol 30:10:25:35 molar ratio), compared to late endosome composition ($9.2\% \pm 5.3\%$ and $21.5\% \pm 8.8\%$, respectively; $P = 0.00223$). This effect may arise from cholesterol in the bilayer, which was reported to inhibit efficient cargo transfer from EVs to recipient cells at the late endosome (17).

Additionally, we determined that the enhanced fusion efficiency observed towards late endosomal composition is not exclusively driven by electrostatic interaction with the negatively charged LBPA, as substitution of LBPA with the equivalently anionic phosphatidylserine (PS) results in a significant decrease in fusion (Fig. 3B; $12.7\% \pm 5.7\%$ membrane mixing for PS-containing LUVs compared to $33.2\% \pm 8.1\%$ for LBPA-containing LUVs; $P = 1.16403E-5$).

The putative EV fusogen is insensitive to preacidification

Viral fusogens typically undergo an irreversible conformational change at low pH (39). Hence, exposing retroviruses to low pH in the absence of target membranes inactivates the fusogen. Since the biogenesis of specific EV subpopulations occurs in the acidic milieu of MVBs (e.g. exosomes) (40), we hypothesized that the conformational change of the putative EV fusogen might be reversible, as shown for the viral fusogen VSV-G (22, 41, 42). To test this hypothesis, we measured the ability of EVs to fuse after acidification and subsequent reneutralization of the pH values prior to incubation with LUVs and reacidification. Membrane mixing efficiency was evaluated under these conditions and compared to both pseudotyped VSV and retroviruses as positive and negative controls, respectively (43). While retroviruses lost their membrane mixing activity after acidification and reneutralization, VSV and EVs exhibited comparable membrane mixing probabilities under the two conditions (Figs. 3B and S5). We conclude that the putative EV fusogen is triggered by low pH but in a reversible manner. These results are consistent with a model wherein EVs are not fusogenic during their biogenesis in the acidic lumen of the MVB, and only become fusion-competent upon release into the neutral pH of the extracellular space. Moreover, these results suggest that the molecular mechanism underlying the reversibility could be due to reversible conformational changes in the putative EV fusogen, as observed for VSV-G (22).

EV fusion intermediates visualized by cryo-TEM

Having demonstrated that the *in vitro* EV-LUV system recapitulates the previously reported protein- and pH-dependence, we




Fig. 3. EV fuse using a lipid-composition dependent reversible mechanism. (A) FRET fusion assay for EVs incubated with LUVs composed of DOPC, early endosome-mimicking LUVs, or late-endosome-mimicking LUVs at pH 5.0. (B) FRET fusion assay for EVs incubated with either late endosome-mimicking LUVs or late endosome-mimicking LUVs with PS substituting LBPA at pH 7.4 (green) and 5.0 (orange). (C) Membrane mixing assay to probe reversibility of the putative EV fusogen. EVs, retroviruses, and VSV viruses were incubated at pH 5.0 and subsequently brought back to pH 7.4 and mixed with LUVs at pH 5.0. Purple-bound and transparent box indicates data also presented in Fig. 2C, obtained from the same experiment.

used cryo-TEM to visualize the interaction (Fig. 4). Membrane fusion intermediate states canonically associated with viral fusion include (i) close contact between the lipid bilayers, (ii) fusion of the outer leaflets to form a hemifusion diaphragm, (iii) fusion of the inner leaflets into an initial fusion pore to allow content mixing, and (iv) expansion of the fusion pore (44–46) (Fig. 4A). EV incubated with LUV at pH 5.0 and 7.4 showed a similar percentage of close contacts between the two vesicle populations ($38.5\% \pm 16.6\%$ and $26.2\% \pm 8.6\%$, respectively; Fig. 4B and F). Remarkably, fusion intermediates including hemifusion (Fig. 4C and F; $6.8\% \pm 2.8\%$), initial pore (Fig. 4D and F; $10.4\% \pm 5.9\%$), and expanded pore (Fig. 4E and F; $8.8\% \pm 1.6\%$) were only apparent at pH 5. LUVs alone displayed some close contacts but no fusion intermediates at both pH 7.4 and 5.0 ($6.9\% \pm 2.6\%$ and $5.4\% \pm 0.9\%$, respectively; Figs. 4F and S6A).

To resolve the 3D ultrastructure of the fusion intermediates and unambiguously determine if content mixing occurs through an expanded pore, we used cryo-ET. Reconstructed tilt series of acidified EVs with LUVs clearly showed content mixing and expanded pore between vesicles, with the two membranes fully merged and a narrow connection between the two vesicular lumens (Figs. 4G and S6B, and Movies S1 and S2). These results demonstrate that EV fusion is triggered by low pH and that membrane mixing using FRET is a bona fide method to measure fusion and the efficiency of cargo delivery under varying conditions.

Discussion

While it has not been unambiguously shown, the hypothesis that EV cargo delivery occurs via membrane fusion is supported by several studies (17–20). Yao et al. showed that membrane mixing of labeled exosomes occurs at the endosomes and that mixing depends on the late endosomal lipid LBPA (18). Similarly, Joshi et al. demonstrated that the release of GFP from the EV lumen occurs at the late endosome and that inhibiting endosome acidification or cholesterol depletion suppresses EV cargo delivery (17). In two separate studies, Bonsergent et al. demonstrated *in vitro* that EV content release to plasma membrane sheets is protein- and pH-dependent and that the delivery can be inhibited by IFITM proteins on the apposing membrane (19, 20). However, these assays could not unambiguously demonstrate that membrane fusion between EV and membranes occurs.

To overcome this challenge, we standardized a robust *in vitro* fusion assay between EVs and LUVs and benchmarked it using viruses. We show that the assay recapitulates all the features previously observed for EV cargo delivery and allows better control over both the environmental conditions and the lipid composition of the target membrane. Moreover, the assay and fusion process can be readily visualized by cryo-EM, providing information on the structural fusion intermediates and their occurrence under different conditions.




Fig. 4. Cryo-EM imaging reveals EV hemifusion intermediates. (A) Illustration showing canonical viral membrane fusion intermediates. Contact: The membrane is tightly in contact (<2 nm) with the apposing membrane and the two bilayers run parallel to each other. Hemifusion: The two proximal leaflets of lipid bilayers have joined and the hemifusion diaphragm is composed of only the two remaining leaflets. Initial pore: The two membranes merge at the contact point, with the two bilayers transitioning continuously from one onto the other. At this stage, the content can mix, but the pores can still collapse and reseal. Expanded pore: The fusion pore increases in diameter and complete content mixing can occur. (B to E) Representative cryo-TEM images of vesicle-vesicle fusion intermediates. Insets show the interaction spot at higher magnification (top panel). Middle panel: outlines showing the two vesicles' membranes defined by luminal gray level distribution. Bottom panel: line profile to evaluate the presence of bilayer-leaflets. Yellow and white lines indicate membrane leaflets in inset and region where line profile was acquired, respectively. (B) Contact between vesicles. (C) Hemifusion: arrow indicates the location where the two bilayers merged into one. (D) Initial pore: white arrow indicates the fusion pore. (E) Expanded pore: dumbbell-shaped pore with an enlarged neck and apparent cargo flow from one vesicle into the other. White arrow indicates the putative extended neck where the vesicles fused. (F) Quantification of interaction intermediates for LUV-LUV and EV-LUV systems at pH 7.4 and 5.0. (G) Tomographic reconstruction of vesicle-vesicle interaction at pH 5.0 revealing content mixing between the vesicles. White arrowhead indicates the fusion pore.

By capitalizing on these advantages, we show that EV fusion is unidirectional *in vitro* and does not require proteins on the target membrane. Moreover, fusion occurs via hemifusion. These features are strikingly similar to viral fusion, suggesting that the EV fusogen or fusogens might share structural similarities, or even common ancestors, with viral fusogens. Moreover, we demonstrate that changes in the delivery efficiency reported for specific lipid compositions (17) or upon pH acidification (19) are directly related to EV fusion.

Remarkably, our results also show that EVs are not inactivated if exposed to acidic pH in the absence of target membranes, sug-

gesting a reversible conformational change of the EV fusogen, similarly to the viral fusogen VSV-G. These results are consistent with a model wherein the EVs (e.g. exosomes) that bud into the acidic lumen of the MVB are in an inactive nonfusogenic state. EVs are then activated at neutral pH after secretion to the extracellular space and fuse in a pH-dependent manner after internalization into target cells. Thus, EVs avoid a paradoxical scenario wherein exposure to acidic pH during assembly would also irreversibly inactivate their fusion machinery.

We have previously suggested that EVs derived from malaria-infected red blood cells (RBCs) can fuse to LUVs that mimic the

lipid composition of the plasma membrane in a pH-independent manner (47). The absence of a pH trigger is consistent with the lack of endocytosis in RBCs, and suggests that the fusion mechanism and the fusogens might be context-dependent. This hypothesis further reinforces the analogy to viruses that have evolved different triggering mechanisms. Therefore, it will be essential to define the fusion mechanism of different subpopulations of EVs and identify the EV fusogens. However, better separation of EVs into structurally and functionally distinct subpopulations remains a confounding challenge.

A benchmarked assay that recapitulates bone fide EV fusion could become an essential tool in identifying the fusion machinery. Candidate proteins could be deleted in producing cells and EV fusogenicity could be evaluated with high throughput. Moreover, showing that isolated EVs maintain their fusogenic activity has the potential to become a gold standard in the study of EVs (25). Understanding the mechanism of EV membrane fusion is essential not only for expanding our knowledge in EV biology but also for developing them into biocompatible and tissue-specific delivery systems.

Materials and methods

Statistical analysis

All experiments were carried out with $n \geq 3$ biological replicates. Statistical analysis was carried out using OriginPro software. In all Figures containing box plots, each dot represents one measurement. Box layouts represent 25 to 75 percentiles of the distribution, whiskers highlight outliers data points, and horizontal black lines represent mean of the distribution. Whenever comparing two conditions, data were analyzed with a two-sample Student's t-test with a significance level of 0.05. Throughout the study, the threshold for statistical significance was considered for P-values ≤ 0.05 , denoted by one asterisk (*), two (**) if $P \leq 0.01$, three (***) if $P < 0.001$, and four (****) if $P \leq 0.0001$.

Cell culture and EV isolation

Extracellular vesicles derived from ovarian cancer cells (OVCAR-3; ATCC-HTB-161) conditioned media were harvested as previously described (48). Briefly, cells were seeded at 10×10^6 cells in a 175 cm² flask in culture media composed of DMEM with 10% EV-free FBS, 1% sodium pyruvate, 1% L-glutamate, and 1% Pen/Strep. When cells had reached 70% confluence (typically 2 days post-seeding), the cells were washed twice with PBS buffer without Ca²⁺ and Mg²⁺ (PBS -/-) and replenished with naive EV-free growth medium. Cell culture media was collected after 48 h and spun at 300 g for 10 min at 4°C to remove large debris and leftover cells, supernatant was collected and spun at 2,000 g for 10 min at 4°C. Supernatant was then collected, spun at 10,000 g for 45 min to remove larger vesicular particles, and filtered through a 0.22 μ m polycarbonate filter. The resulting media was used for vesicle isolation within 2 days or frozen at -80°C for biochemical analysis.

Following filtration, the cell culture media was spun using an ultracentrifuge, a Ti45 rotor (Beckman Coulter, Fullerton, CA, USA) at 100,000 g for 4 h at 4°C. Supernatant was removed and the resulting pellet was washed once with PBS -/- and resuspended in PBS -/-. For membrane mixing experiments, cell culture media was incubated with 0.01% v/v of 2.5 mM DiI (Merck, CAT: 42364) and DiD (Thermo Fisher, D7757) 1:1 mixture in DMSO at 37°C for 30 min.

Density gradient ultracentrifugation

Following differential ultracentrifugation, EVs were fractionated by OptiPrep density gradient ultracentrifugation (100,000 \times g, 18 h, 4°C) using a SW41 rotor (Beckman Coulter, Fullerton, CA, USA) through a continuous 5% to 40% OptiPrep (Sigma-Aldrich, D1556) gradient. Fractions (1 mL) were collected from the top of the gradient for further analysis and density was verified by measuring the mass of a 100 μ L aliquot of each fraction. Fractions of EV-specific density were then pooled together and subsequently concentrated via ultracentrifugation (100,000 \times g, 4 h, 4°C) through a 20% w/v sucrose cushion in a SW41 rotor (Beckman Coulter, Fullerton, CA, USA). The resulting supernatant was discarded, and the EV pellet was resuspended in PBS -/.

Preparation of vesicle-depleted fetal bovine serum (EV-free FBS)

FBS was depleted from extracellular vesicles by two rounds of ultracentrifugation at 100,000 g for 18 h in a Beckman Ti45 rotor; in each round, the supernatant was collected and the large pellet at the bottom of the tube was discarded. After the final round of ultracentrifugation, supernatant was collected and filtered through a 0.22 μ m pore membrane, aliquoted, and stored at -20°C for preparation of an EV-free growth medium.

Nanoparticle tracking analysis

EV size and concentration distribution analysis was performed using an NTA (Malvern Instruments Ltd., NanoSight NS300) at 20°C. Sample size distributions were obtained in a liquid suspension (1:500 to 1:1000 dilution in PBS -/-) by analyzing Brownian motion via light scattering. The camera level was set to 13 and gain to 1, with a 405 nm laser unit without filter, following the manufacturer's instruction. The data were analyzed using NTA 2.1 software (NanoSight) and plotted using the OriginPro software.

Western blot analysis

Equal volumes of pelleted OptiPrep fractions and 20 to 30 μ g of protein cell lysates were mixed with 4 \times Laemmli sample buffer (4% SDS, 10% mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, and 0.125M Tris-HCl) and boiled at 96°C for 5 to 10 min. Samples were subjected to electrophoresis using 7% to 15% SDS-PAGE gels in TG-SDS running buffer (Bio-Lab) at constant 150 V for 1 h. Proteins were electrotransferred onto nitrocellulose membranes using a standard tank transfer protocol with TG transfer buffer (Bio-Lab) with 20% methanol. Membranes were blocked with 5% nonfat milk dissolved in TBS containing 0.1% Tween (TBST) for 1 h and incubated with one of the following primary antibodies either overnight at 4°C or 1 h at room temperature. (dilution, company, catalog number): anti-CD9 (1:1,000, Abcam, ab92726), anti-PTGFRN (1:1,000, R&D Systems, MAB10043-100), anti-CD63 (1:1,000, Proteintech, 25682-1-AP), anti-Alix (1:1,000, Proteintech, 12422-1-AP), and anti-Tom20 (1:1,000, Abcam, ab56783). The primary antibodies were diluted in 5% nonfat dry milk in TBST. Membranes were washed three times for 10 min at room temperature with TBST and incubated with either antimouse IgG-HRP (1:20,000, Abcam, ab6728) or antirabbit IgG-HRP (1:20,000, Abcam, ab6721) diluted in TBST for 1 h. Membranes were washed three times for 10 min with TBST. EZ-ECL (Biological Industries Ltd.) was used for detection with the sequential visualization using the Odyssey Fc Dual-Mode Imaging System (Li-COR Biosciences, Lincoln, NE, USA). Each presented Western blot is a representative image of three separate biological replicates.

Preparation of LUVs

LUVs were prepared with a lipid composition either of DOPC or mimicking the membranes of early and late endosomes. For early endosome-mimicking LUVs, the lipid content was DOPC:DOPE:SM:chol 30:10:25:35, while late endosome-mimicking LUVs were composed of LBPA:DOPE:DOPC 70:5:25 (molar ratio) to mimic the cholesterol sequestration and enrichment of late endosomal lipid LBPA (49). Additionally, to test the role of electrostatic interaction in EV fusion, we prepared LUVs mimicking late endosomal composition with LBPA substituted by PS for a final lipid composition of DOPS:DOPE:DOPC 70:5:25. Lipid solutions in chloroform of the different phospholipid species were mixed to the desired molar ratios in a glass vial, and the organic solvent was evaporated by 12 h of vacuum pumping. For labeled LUVs, the lipids were stained at a 2% mol/mol fraction of DiI and DiD in chloroform before evaporation. The lipid film was then hydrated with PBS $-/-$ at 50°C to reach the desired concentration and gently vortexed. The resulting MLV suspension was then sonicated for 10 min to disperse larger aggregates and the liposomal suspension was extruded 21 times through polycarbonate filters (100 nm pore size, Avanti Polar Lipids) using a miniextruder (Avanti Polar Lipids). Size and concentration were verified using NTA and the liposomal suspension was used within 2 weeks from extrusion.

Retrovirus preparation

Retroviruses were generated by transfecting pBABE-Puro plasmids, a gift from Hartmut Land & Jay Morgenstern & Bob Weinberg [Addgene plasmid # 1764, (50)], into Platinum-E Cells (Cell Biolabs, Inc.). Twenty-four hours prior to transfection, 3×10^6 were seeded in a 10-cm culture dish according to manufacturer instructions. Ten micrograms of retroviral plasmid DNA was transfected using jetPRIME transfection reagent (PolyPlus transfection). Five milliliters of viral suspension was collected from the conditioned media 48 h post-transfection and centrifuged at 1,000 *g* for 10 min at room temperature to remove cell debris. The supernatant was carefully transferred into another ice-cooled falcon tube. Virions were concentrated by pelleting at 100,000 *g* through a 20% sucrose cushion for 2 h and resuspended in PBS $-/-$. The concentrated viruses were used for further experiments.

Preparation of VSV Δ G-G pseudoviruses

Baby hamster kidney cells (BHK-21; ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco), 1% Penn/Strep, 7% to 10% Fetal bovine serum (FBS, Biological Industries, Kibbutz Beit Haemek, Israel) at 37°C in 5% CO₂. For maintenance, BHK-21 cells were grown at 7% FBS. For pseudovirus preparations, BHK-21 cells were grown at 10% FBS.

To generate VSV-G-complemented VSV Δ G pseudoviruses (VSV Δ G-G), 200,000 BHK-21 cells were seeded in 5 mL of medium. Cells were transfected at \sim 70% confluency with plasmids encoding VSV-G (Indiana) glycoprotein (1 μ g/mL) (51). After 24 h incubation, transfected cells were infected with VSV Δ G-G helper viruses at a multiplicity of infection (MOI) of 5 for 1 h at 37°C in a 5% CO₂ incubator rocking every 15 min. Twenty-four hours post-infection, the cells were scraped off and transferred with the supernatant into ice-cooled falcon tubes. The cell debris were removed by centrifuge at 500 *g* for 10 min at 4°C. The supernatant was carefully transferred into another ice-cooled falcon tube. Virions were concentrated by pelleting at 100,000 *g* through a 20% sucrose cushion for 2 h and resuspended in PBS $-/-$. The concentrated viruses were used for further experiments.

Precidification of virions and EVs

EVs or viruses' samples post-isolation were acidified to pH 5.0 by adding 7% v/v of HCl 100 mM and incubated at 4°C for 45 min. Subsequently, 6.5% v/v of NaOH 100 mM was added to re-equilibrate the pH to 7.4 and samples were maintained at 4°C for at least 1 h before being incubated with liposomes for membrane mixing assay (39, 52).

Membrane fluorescence labeling

To fluorescently label EVs and viruses, filtered conditioned media from either EV-producing or virion-producing cells was mixed with 2.5 mM 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (DiI, Merck, CAT: 42,364) and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD, Thermo Fisher, D7757) in DMSO at 0.1% v/v. Media with the DiI-DiD solution was incubated at 37°C for 30 min. EVs were isolated using an ultracentrifuge with a Ti45 rotor (Beckman Coulter, Fullerton, CA, USA) at 100,000 *g* for 4 h at 4°C. The supernatant was removed and the resulting pellet was washed once with PBS $-/-$ and resuspended in PBS $-/-$.

Membrane mixing assay

All experiments were performed using a Cytation 5 Imaging Reader plate reader (BioTek) with a 96-well plate. DiI (Merck, CAT: 42,364) and DiD (Thermo Fisher, D7757) labeled EVs and unlabeled LUVs were diluted in PBS $-/-$ per well to reach a final ratio of 1:9 fluorescent particles to nonlabeled vesicles, and fluorescence intensity of the donor (DiI) was recorded every 60 s for 30 min, with excitation wavelength of 530 nm and emission wavelengths of 570 nm. Subsequently, a volume fraction of HCl 100 mM was added to reach the desired pH and DiI fluorescence intensity was recorded for 1 h every 60 s. Finally, Triton X-100 was added to each well to reach 0.1% final concentration and fluorescence intensity was recorded for 15 min every 60 s. The emission fluorescence for each time point was measured as I_n . The emission fluorescence of the untreated liposomes was measured as I_0 , and that of the liposomes solubilized with 0.1% TRITON X-100 was defined as I_{100} . The percentage of membrane mixing at each time point is defined as: donor relative intensity (% of TRITON X-100) = $(I_n - I_0) \times 100 / (I_{100} - I_0)$. All measurements were performed at 37°C. The data were analyzed by using Gen5™ v. 3.04 software (BioTek).

Size distribution NTA analysis for EV fusion events

LUVs and EVs were mixed in a 1:1 ratio (particles:particles) to a final concentration of 1×10^8 to 10×10^8 particles/mL in 1 mL of filtered PBS $-/-$ and kept at 4°C for 1 h. Prior to size NTA measurement, a 7% v/v fraction of either PBS $-/-$ or HCl 100 mM was added to maintain physiological pH or reach pH 5.0, respectively. Samples were incubated at 37°C for 30 min and the size distribution was subsequently measured using a NanoSight NS300. Briefly, approximately 1 mL solution was loaded into the sample chamber of an LM10 unit (NanoSight) and five videos of 60 s were recorded. Data analysis was performed with NTA 2.1 software (NanoSight). The resulting size distribution curves were then analyzed by considering the average diameter of each biological repeat, obtained from the instrumentation analysis software.

EV protein digestion by PK

Isolated EVs in PBS $-/-$ were incubated for 45 min at 37°C in the presence of 20 $\mu\text{g}/\text{mL}$ PK (Invitrogen, AM2546). Following incubation, the sample was placed on ice and the proteinase activity was quenched with phenylmethylsulfonyl fluoride (stock solution dissolved in DMSO; Merck, P7626) for a final concentration of 2 mM.

Preparation of cryo-TEM samples

Cryo-EM samples of both EVs and LUVs were prepared on either lacey carbon or C-flat EM grids (Electron Microscopy Sciences, USA), on which 10 nm protein A colloidal gold particles (Au-NP) were preadsorbed (Aurion, Netherlands). Au-NP adsorbed grids were then glow-discharged (30 s, 25 mA) in a Pelco EasiGlow system. An aliquot (3.5 μL) of the aqueous solution of the sample was applied to the carbon side of EM grids, which was then incubated in the humidity chamber of the instrument for 7 min at 100% humidity and room temperature, and subsequently blotted for 4.0 s at blot force -10 and plunge-frozen into the precooled liquid ethane with a Vitrobot Mark IV (FEI, USA).

Cryo-TEM

Cryo-electron micrographs of vitrified samples were collected using a transmission electron microscope Talos Arctica G3 TEM/STEM (Thermo Fisher Scientific, USA), equipped with a OneView camera (Gatan) at accelerating voltage of 200 kV. Grid mapping and image acquisition were performed using SerialEM software (53) at a nominal magnification of 180 \times and 13,500 \times , respectively. High-magnification images were recorded at 73,000 \times nominal magnification (0.411 nm pixel size) with a $-3.5 \mu\text{m}$ defocus value. To minimize radiation damage during image acquisition, low-dose mode in SerialEM software was used and electron dose was kept below 100 $\text{e}/\text{\AA}^2$.

Cryo-ET

Samples were prepared as for cryo-TEM (described above) with some modifications. Prior to plunging, samples were mixed 50:1 with a suspension of 10 nm Au-NP (Aurion, Netherlands) to serve as fiducial markers for reconstruction. Tilt series were collected using a transmission electron microscope (Titan Krios 3Gi STEM/TEM, Thermo Fisher Scientific, USA) at 300 kV equipped with a Gatan K3 direct detector mounted at the end of a Gatan BioQuantum energy filter set in zero-energy-loss mode (slit width, 20 eV). Tilt series were acquired in low-dose mode using SerialEM (53) software at a nominal magnification of 42,000 \times with an angular range from -60° to $+60^\circ$, an angular increment of 4° using a $-3.5 \mu\text{m}$ defocus, 70 μm objective aperture, 0.214 nm per pixel, and a maximal total dose of 150 $\text{e}/\text{\AA}^2$. Tomograms were reconstructed using the weighted back-projection technique in the IMOD software suite (54) with a SIRT-like filter equivalent to five iterations, following nonlinear anisotropic diffusion (NAD) denoising (55) if indicated.

EM image analysis of vesicles

The spatial distribution of gray levels from the EV or LUV luminal content was analyzed from images collected both via cryo-TEM or reconstructed from cryo-ET tilt series using three separate approaches: (1) peak analysis of the angularly averaged radial profile, (2) analysis of the spatial autocorrelation function, and (3) analysis of the Fourier transform. For all three analyses, a 120 \times 120

pixel square region of the luminal portion of the vesicle was selected from each image and converted to 8-bit format.

For analyses (1) and (2), two randomly selected pools of EVs and LUVs ($n = 10$) were utilized. Analysis (3) was conducted on two randomly selected pools of EVs and LUVs ($n = 50$, from three separate experiments).

Spatial distribution of gray level was quantified by measuring a radially averaged line profile of the lumen section using the Radial Profile Angle plugin of Fiji (56), which was subsequently smoothed using a 10-point Savitzky-Golay using the OriginPro software. Finally, a peak finding analysis using the OriginPro software was performed to obtain the peak positions and the corresponding peak-to-peak distances.

Additionally, the spatial autocorrelation function for each luminal region was measured using the AutoCorrelation Function plugin of Fiji.

For Fourier analysis of the images, 8-bit images of the luminal regions were thresholded at the same interval (110 gray value cut-off) to obtain binary images of the lumen. For each binary image, an FFT was applied using the Fiji command, resulting in 128 \times 128 pixels FFT images. The resulting FFT image radial profile was then measured using the Radial Profile Angle plugin of Fiji.

Acknowledgments

We thank members of the Avinoam, Regev-Rudzki, and Gil labs for discussions. O.A. is an incumbent of the Miriam Berman Presidential Development Chair. N.R.R. is the incumbent of the Enid Barden and Aaron J. Jade President's Development Chair for New Scientists in Memory of Cantor John Y. Jade.

Supplementary Material

Supplementary material is available at [PNAS Nexus](#) online.

Funding

This research was supported by the Israel Science Foundation (grant no. 1637/20), within the Israel Precision Medicine Partnership (IPMP) program to, O.A., N.R.R., and Z.G. This study was also supported by the European Research Council (ERC StG # 851080 to O.A.). O.A. also acknowledges funding from the David Barton Center for Research on the Chemistry of Life and the Ruth and Herman Albert Scholarship Program for New Scientists. The research of N.R.R. is supported by the Benozio Endowment Fund for the Advancement of Science, the Jeanne and Joseph Nissim Foundation for Life Sciences Research, and the Samuel M. Soref and Helene K. Soref Foundation. N.R.R. is grateful for the support from the European Research Council (ERC) (grant agreement no. 757743) and from the Israel Science Foundation (ISF) (Grant Application no. 570/21). M.I.M. was supported by the Lombroso Postdoctoral Fellowship for Cancer Research.

Authors' Contributions

M.I.M., N.R.R., and O.A. conceived and designed the experiments. M.I.M. and P.B. performed most of the experiments. E.O.P., S.K., G.Z., P.A.K., and Y.E.A. produced viruses and assisted in cell maintenance and biochemistry. T.N., L.G., and Z.G. assisted with EV assays. M.I.M., N.R.R. and O.A. wrote the manuscript with inputs from all authors.

Data Availability

All data are included in the manuscript and/or Supplementary Material.

References

- Wortzel I, Dror S, Kenific CM, Lyden D. 2019. Exosome-mediated metastasis: communication from a distance. *Dev Cell*. 49:347–360.
- Boomgard AC, Clancy JW, D'Souza-Schorey C. 2020. Breaking bad: extracellular vesicles provoke tumorigenic responses under oxygen deprivation. *Dev Cell*. 55:111–113.
- Kalluri R, LeBleu VS. 2020. The biology, function, and biomedical applications of exosomes. *Science*. 367:6478.
- Yang C, Robbins PD. 2011. The roles of tumor-derived exosomes in cancer pathogenesis. *Clin Dev Immunol*. 2011:842849.
- García-Silva S, et al. 2021. Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. *Nat Cancer*. 2:1387–1405.
- Li XB, Zhang ZR, Schluesener HJ, Xu SQ. 2006. Role of exosomes in immune regulation. *J Cell Mol Med*. 10:364–375.
- Tian Y, et al. 2014. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. *Biomaterials*. 35:2383–2390.
- LeBleu VS, Kalluri R. 2020. Exosomes as a multicomponent biomarker platform in cancer. *Trends Cancer* 6:767–774.
- Zhang H, et al. 2018. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. *Nat Cell Biol*. 20:332–343.
- van Niel G, D'Angelo G, Raposo G. 2018. Shedding light on the cell biology of extracellular vesicles. *Nat Rev Mol Cell Biol*. 19:213–228.
- Valcz G, et al. 2019. *En bloc* release of MVB-like small extracellular vesicle clusters by colorectal carcinoma cells. *J Extracell Vesicles*. 8:1596668.
- Mulcahy LA, Pink RC, Carter DRF. 2014. Routes and mechanisms of extracellular vesicle uptake. *J Extracell Vesicles*. 3(1).
- Wells WA. 2003. When is a virus an exosome? *J Cell Biol*. 162:960.
- Hoeh EN, Cremer T, Gallo RC, Margolis LB. 2016. Extracellular vesicles and viruses: are they close relatives? *Proc Natl Acad Sci USA*. 113:9155.
- Yamauchi Y, Helenius A. 2013. Virus entry at a glance. *J Cell Sci*. 126:1289–1295.
- Mebatsion T, Konig M, Conzelmann KK. 1996. Budding of rabies virus particles in the absence of the spike glycoprotein. *Cell*. 84:941–951.
- Joshi BS, de Beer MA, Giepmans BNG, Zuhorn IS. 2020. Endocytosis of extracellular vesicles and release of their cargo from endosomes. *ACS Nano*. 14:4444–4455.
- Yao Z, et al. 2018. Exosomes exploit the virus entry machinery and pathway to transmit alpha interferon-induced antiviral activity. *J Virol*. 92:e01578–18.
- Bonsergent E, Lavieu G. 2019. Content release of extracellular vesicles in a cell-free extract. *FEBS Lett*. 593:1983–1992.
- Bonsergent E, et al. 2021. Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells. *Nat Commun*. 12:1–11.
- Mitsui K, Koshimura Y, Yoshikawa Y, Matsushita M, Kanazawa H. 2011. The endosomal Na(+)/H(+) exchanger contributes to multivesicular body formation by regulating the recruitment of ESCRT-0 Vps27p to the endosomal membrane. *J Biol Chem*. 286:37625–37638.
- Kim IS, et al. 2017. Mechanism of membrane fusion induced by vesicular stomatitis virus G protein. *Proc Natl Acad Sci USA*. 114:E28–E36.
- Yao Y, Ghosh K, Epand RF, Epand RM, Ghosh HP. 2003. Membrane fusion activity of vesicular stomatitis virus glycoprotein G is induced by low pH but not by heat or denaturant. *Virology*. 310:319–332.
- Regev-Rudzki N, et al. 2013. Cell–cell communication between malaria-infected red blood cells via exosome-like vesicles. *Cell*. 153:1120–1133.
- Théry C, et al. 2018. Minimal information for studies of extracellular vesicles 2018 (MISEV 2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles*. 7:1535750.
- Gupta S, et al. 2018. An improvised one-step sucrose cushion ultracentrifugation method for exosome isolation from culture supernatants of mesenchymal stem cells. *Stem Cell Res Ther*. 9:180.
- Nunes-Correia I, et al. 2002. Fluorescent probes for monitoring virus fusion kinetics: comparative evaluation of reliability. *Biochim Biophys Acta Biomembr*. 1561:65–75.
- Stegmann T, Nir S, Wilschut J. 1989. Membrane fusion activity of influenza virus. Effects of gangliosides and negatively charged phospholipids in target liposomes. *Biochemistry*. 28:1698–1704.
- Struck DK, Hoekstra D, Pagano RE. 1981. Use of resonance energy transfer to monitor membrane fusion. *Biochemistry*. 20:4093–4099.
- Leikina E, et al. 2018. Myomaker and myomerger work independently to control distinct steps of membrane remodeling during myoblast Fusion. *Dev Cell*. 46:767–780.e7.
- Cardone G, et al. 2012. Visualization of the two-step fusion process of the retrovirus avian sarcoma/leukosis virus by cryo-electron tomography. *J Virol*. 86:12129–12137.
- van den Bogaart G, et al. 2010. One SNARE complex is sufficient for membrane fusion. *Nat Struct Mol Biol*. 17:358–364.
- Huotari J, Helenius A. 2011. Endosome maturation. *EMBO J*. 30:3481–3500.
- Stegmann T, Hoekstra D, Scherphof G, Wilschut J. 1985. Kinetics of pH-dependent fusion between influenza virus and liposomes. *Biochemistry*. 24:3107–3113.
- Cvjetkovic A, et al. 2016. Detailed analysis of protein topology of extracellular vesicles—evidence of unconventional membrane protein orientation. *Sci Rep*. 6:1–12.
- Coleman BM, Hanssen E, Lawson VA, Hill AF. 2012. Prion-infected cells regulate the release of exosomes with distinct ultrastructural features. *FASEB J*. 26:4160–4173.
- Dooley K, et al. 2021. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. *Mol Ther*. 29:1729–1743.
- Yang ST, Kiessling V, Simmons JA, White JM, Tamm LK. 2015. HIV gp41-mediated membrane fusion occurs at edges of cholesterol-rich lipid domains. *Nat Chem Biol*. 11:424–431.
- Stegmann T, Booy FP, Wilschut J. 1987. Effects of low pH on influenza virus. Activation and inactivation of the membrane fusion capacity of the hemagglutinin. *J Biol Chem*. 262:17744–17749.
- Verweij FJ, et al. 2018. Quantifying exosome secretion from single cells reveals a modulatory role for GPCR signaling. *J Cell Biol*. 217:1129–1142.
- Puri A, et al. 1988. Activation of vesicular stomatitis virus fusion with cells by pretreatment at low pH*. *J Biol Chem*. 263:4749–4753.

42. Beilstein A, Frauke, *et al.* 2020. Identification of a pH-sensitive switch in VSV-G and a crystal structure of the G pre-fusion state highlight the VSV-G structural transition pathway. *Cell Rep.* 32:108042.
43. Gaudin Y. 2000. Reversibility in fusion protein conformational changes. The intriguing case of rhabdovirus-induced membrane fusion. *Subcell Biochem.* 34:379–408.
44. Chernomordik LV, Kozlov MM. 2008. Mechanics of membrane fusion. *Nat Struct Mol Biol.* 15:675–683.
45. Fontana J, Steven AC. 2015. Influenza virus-mediated membrane fusion: structural insights from electron microscopy. *Arch Biochem Biophys.* 581:86–97.
46. Chlanda P, *et al.* 2016. The hemifusion structure induced by influenza virus haemagglutinin is determined by physical properties of the target membranes. *Nat Microbiol.* 1:16050.
47. Dekel E, *et al.* 2021. 20S proteasomes secreted by the malaria parasite promote its growth. *Nat Commun.* 12:1172.
48. Théry C, Amigorena S, Raposo G, Clayton A. 2006. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr Protoc Cell Biol.* 30:3.22.1–3.22.29.
49. Erazo-Oliveras A, *et al.* 2016. The late endosome and its lipid BMP act as gateways for efficient cytosolic access of the delivery agent dTAT and its macromolecular cargos. *Cell Chem Biol.* 23:598–607.
50. Morgenstern JP, Land H. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. *Nucleic Acids Res.* 18:3587–3596.
51. Takada A, *et al.* 1997. A system for functional analysis of Ebola virus glycoprotein. *Proc Natl Acad Sci.* 94:14764–14769.
52. Weiss C, Clark HF. 1985. Rapid inactivation of rotaviruses by exposure to acid buffer or acidic gastric juice. *J Gen Virol.* 66:2725–2730.
53. Mastronarde DN. 2005. Automated electron microscope tomography using robust prediction of specimen movements. *J Struct Biol.* 152:36–51.
54. Kremer JR, Mastronarde DN, McIntosh JR. 1996. Computer visualization of three-dimensional image data using IMOD. *J Struct Biol.* 116:71–76.
55. Frangakis AS, Hegerl R. 2001. Noise reduction in electron tomographic reconstructions using nonlinear anisotropic diffusion. *J Struct Biol.* 135:239–250.
56. Schindelin J, *et al.* 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods.* 9:676–682.